Table.
Summary of Reported Patients with Anti-PD-1 Antibody-induced ILD Including the Present Case.
| Reference | Age/sex | Cancer type | Agent | Pattern of ILD | Method of diagnosis | BALF findings | Treatment for ILD | Outcome | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell counts (×105/mL) | AM (%) | Lym (%) | Neu (%) | Eos (%) | ||||||||
| (7) | 70/M | Melanoma | Nivo | ARDS | Clinical | ND | ND | ND | ND | ND | IV steroids, IV IFX | Improved |
| (7) | 38/F | Melanoma | Nivo | ARDS | Clinical | ND | ND | ND | ND | ND | IV steroids, IV IFX | Dead |
| (7) | 58/M | Melanoma | Nivo | NSIP | Clinical | ND | ND | ND | ND | ND | Oral steroids | Improved |
| (8) | 70/F | Melanoma | Nivo | OP | Biopsy | 7.7 | 38.5 | 43.5 | 13.0 | 0 | Oral steroids | Improved |
| (9) | 70/F | Melanoma | Nivo | OP | Biopsy | 2.76 | 58.9 | 37.3 | 2.3 | 1.5 | IV steroids | Improved |
| (10) | 35/F | Melanoma | Nivo | DAD | Autopsy | ND | ND | ND | ND | ND | Not described | Dead |
| (11) | 73/F | Melanoma | Nivo | DAD | Clinical | 3.1 | 77.7 | 8.7 | 14.3 | ND | mPSL pulse, IVCY | Improved |
| (12) | 64/F | Melanoma | Pembro | OP | Clinical | ND | 60.7 | 28.7 | ND | ND | IV steroids | Improved |
| (13) | 70/M | Sarcomatoid carcinoma of the lung |
Nivo | OP | Clinical | 11.7 | 65.0 | 32.5 | 2.0 | 0.5 | Oral steroids | Improved |
| Present case | 68/M | Melanoma | Nivo | AFOP | Biopsy | 6.0 | 5.7 | 53.6 | 30.1 | 10.6 | mPSL pulse | Improved |
ILD: interstitial lung disease, PD-1: programmed death-1, BALF: bronchoalveolar lavage fluid, AM: alveolar macrophages, Lym: lymphocytes, Neu: neutrophiles, Eos: eosinophiles, ND: not described, Nivo: nivolumab, Pembro: pembrolizumab, ARDS: acute respiratory distress syndrome, NSIP: nonspecific interstitial pneumonia, OP: organizing pneumonia, DAD: diffuse alveolar damage, AFOP: acute fibrinous and organizing pneumonia, IV: intravenous, IFX: infliximab, mPSL: methylprednisolone, IVCY: intravenous cyclophosphamide pulse